Trial reportDiabetologia2009
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
Trial report in Diabetologia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 5 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020Pooled it
- Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.Breast cancer research : BCR · 2015Pooled it
- Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.Current drug safety · 2013Pooled it
- Diabetes: glycaemic control in type 2 (drug treatments).BMJ clinical evidence · 2012Pooled it
- Pooled it
- Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.Journal of diabetes and its complicationsTrial
- Article
- Review
- The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients.Frontiers in oncology · 2020Article
- Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study.Breast cancer research : BCR · 2018Observational
- Insulin glargine use and breast cancer risk: Associations with cumulative exposure.Acta oncologica (Stockholm, Sweden) · 2016Article
- Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism.Scientific reports · 2016Article
- Impaired glucose metabolism treatment and carcinogenesis.Oncology letters · 2015Article
- Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Vascular health and risk management · 2015Review
- Importance of Beta Cell Function for the Treatment of Type 2 Diabetes.Journal of clinical medicine · 2014Review
- Diabetes and cancer: two diseases with obesity as a common risk factor.Diabetes, obesity & metabolism · 2014Review
- Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin.PloS one · 2014Article
- Article
- Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.Diabetes care · 2013Article
- Insulin therapy and cancer.Diabetes care · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.